Cystic fibrosis foundation pulmonary guideline pharmacologic approaches to prevention and Eradication of Initial Pseudomonas aeruginosa Infection

Peter J. Mogayzel, Edward T. Naureckas, Karen A. Robinson, Cynthia Brady, Margaret Frank Guill, Thomas Lahiri, Lisa Lubsch, Jane Matsui, Christopher M. Oermann, Felix Ratjen, Margaret Rosenfeld, Richard H. Simon, Leslie Hazle, Kathy Sabadosa, Bruce C. Marshall, Gary Mueller, Denis Hadjiliadis, Jeffrey B. Hoag

Research output: Contribution to journalReview article

78 Citations (Scopus)

Abstract

Description: The Cystic Fibrosis (CF) Foundation developed clinical care guidelines for the prevention of Pseudomonas aeruginosa infection, the treatment of initial P. aeruginosa infection, and the use of bronchoscopy to obtain routine airway cultures in individuals with CF.

Methods: A multidisciplinary committee developed questions about the prevention and treatment of initial P. aeruginosa infection and the use of bronchoscopy to obtain routine airway cultures. The outcome measure of interest was cultures without P. aeruginosa growth. Systematic reviews of PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials were conducted in May 2012 and August 2013. Searches combined controlled vocabulary terms and text words for CF and terms relevant to each question. The entire committee reviewed the evidence, and final recommendation statements were graded using the U.S. Preventive Services Task Force system.

Recommendation 2: The CF Foundation recommends against the use of prophylactic antipseudomonal antibiotics to prevent the acquisition P. aeruginosa (certainty of net benefit, moderate; estimate of net benefit, zero; grade of recommendation, D).

Recommendation 3: The CF Foundation recommends routine oropharyngeal cultures rather than bronchoalveolar lavage cultures obtained by bronchoscopy in individuals with CF who cannot expectorate sputum to determine if they are infected with P. aeruginosa (certainty of net benefit, moderate; estimate of net benefit, moderate; grade of recommendation, B).

Recommendation 1: The CF Foundation strongly recommends inhaled antibiotic therapy for the treatment of initial or new growth of P. aeruginosa from an airway culture (certainty of net benefit, high; estimate of net benefit, substantial; grade of recommendation, A). The favored antibiotic regimen is inhaled tobramycin (300 mg twice daily) for 28 days.

Original languageEnglish (US)
Pages (from-to)1640-1650
Number of pages11
JournalAnnals of the American Thoracic Society
Volume11
Issue number10
DOIs
StatePublished - Jan 1 2014

Fingerprint

Pseudomonas Infections
Cystic Fibrosis
Pseudomonas aeruginosa
Guidelines
Bronchoscopy
Anti-Bacterial Agents
Controlled Vocabulary
Tobramycin
Bronchoalveolar Lavage
Advisory Committees
Therapeutics
Growth
Sputum
PubMed
Outcome Assessment (Health Care)

Keywords

  • Airway infection
  • Antipseudomonal vaccine
  • Bronchoscopy
  • Inhaled antibiotics
  • Oropharyngeal culture

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Cystic fibrosis foundation pulmonary guideline pharmacologic approaches to prevention and Eradication of Initial Pseudomonas aeruginosa Infection. / Mogayzel, Peter J.; Naureckas, Edward T.; Robinson, Karen A.; Brady, Cynthia; Guill, Margaret Frank; Lahiri, Thomas; Lubsch, Lisa; Matsui, Jane; Oermann, Christopher M.; Ratjen, Felix; Rosenfeld, Margaret; Simon, Richard H.; Hazle, Leslie; Sabadosa, Kathy; Marshall, Bruce C.; Mueller, Gary; Hadjiliadis, Denis; Hoag, Jeffrey B.

In: Annals of the American Thoracic Society, Vol. 11, No. 10, 01.01.2014, p. 1640-1650.

Research output: Contribution to journalReview article

Mogayzel, PJ, Naureckas, ET, Robinson, KA, Brady, C, Guill, MF, Lahiri, T, Lubsch, L, Matsui, J, Oermann, CM, Ratjen, F, Rosenfeld, M, Simon, RH, Hazle, L, Sabadosa, K, Marshall, BC, Mueller, G, Hadjiliadis, D & Hoag, JB 2014, 'Cystic fibrosis foundation pulmonary guideline pharmacologic approaches to prevention and Eradication of Initial Pseudomonas aeruginosa Infection', Annals of the American Thoracic Society, vol. 11, no. 10, pp. 1640-1650. https://doi.org/10.1513/AnnalsATS.201404-166OC
Mogayzel, Peter J. ; Naureckas, Edward T. ; Robinson, Karen A. ; Brady, Cynthia ; Guill, Margaret Frank ; Lahiri, Thomas ; Lubsch, Lisa ; Matsui, Jane ; Oermann, Christopher M. ; Ratjen, Felix ; Rosenfeld, Margaret ; Simon, Richard H. ; Hazle, Leslie ; Sabadosa, Kathy ; Marshall, Bruce C. ; Mueller, Gary ; Hadjiliadis, Denis ; Hoag, Jeffrey B. / Cystic fibrosis foundation pulmonary guideline pharmacologic approaches to prevention and Eradication of Initial Pseudomonas aeruginosa Infection. In: Annals of the American Thoracic Society. 2014 ; Vol. 11, No. 10. pp. 1640-1650.
@article{37e975cdb1814adda63bfa26cf1cf257,
title = "Cystic fibrosis foundation pulmonary guideline pharmacologic approaches to prevention and Eradication of Initial Pseudomonas aeruginosa Infection",
abstract = "Description: The Cystic Fibrosis (CF) Foundation developed clinical care guidelines for the prevention of Pseudomonas aeruginosa infection, the treatment of initial P. aeruginosa infection, and the use of bronchoscopy to obtain routine airway cultures in individuals with CF.Methods: A multidisciplinary committee developed questions about the prevention and treatment of initial P. aeruginosa infection and the use of bronchoscopy to obtain routine airway cultures. The outcome measure of interest was cultures without P. aeruginosa growth. Systematic reviews of PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials were conducted in May 2012 and August 2013. Searches combined controlled vocabulary terms and text words for CF and terms relevant to each question. The entire committee reviewed the evidence, and final recommendation statements were graded using the U.S. Preventive Services Task Force system.Recommendation 2: The CF Foundation recommends against the use of prophylactic antipseudomonal antibiotics to prevent the acquisition P. aeruginosa (certainty of net benefit, moderate; estimate of net benefit, zero; grade of recommendation, D).Recommendation 3: The CF Foundation recommends routine oropharyngeal cultures rather than bronchoalveolar lavage cultures obtained by bronchoscopy in individuals with CF who cannot expectorate sputum to determine if they are infected with P. aeruginosa (certainty of net benefit, moderate; estimate of net benefit, moderate; grade of recommendation, B).Recommendation 1: The CF Foundation strongly recommends inhaled antibiotic therapy for the treatment of initial or new growth of P. aeruginosa from an airway culture (certainty of net benefit, high; estimate of net benefit, substantial; grade of recommendation, A). The favored antibiotic regimen is inhaled tobramycin (300 mg twice daily) for 28 days.",
keywords = "Airway infection, Antipseudomonal vaccine, Bronchoscopy, Inhaled antibiotics, Oropharyngeal culture",
author = "Mogayzel, {Peter J.} and Naureckas, {Edward T.} and Robinson, {Karen A.} and Cynthia Brady and Guill, {Margaret Frank} and Thomas Lahiri and Lisa Lubsch and Jane Matsui and Oermann, {Christopher M.} and Felix Ratjen and Margaret Rosenfeld and Simon, {Richard H.} and Leslie Hazle and Kathy Sabadosa and Marshall, {Bruce C.} and Gary Mueller and Denis Hadjiliadis and Hoag, {Jeffrey B.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1513/AnnalsATS.201404-166OC",
language = "English (US)",
volume = "11",
pages = "1640--1650",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "10",

}

TY - JOUR

T1 - Cystic fibrosis foundation pulmonary guideline pharmacologic approaches to prevention and Eradication of Initial Pseudomonas aeruginosa Infection

AU - Mogayzel, Peter J.

AU - Naureckas, Edward T.

AU - Robinson, Karen A.

AU - Brady, Cynthia

AU - Guill, Margaret Frank

AU - Lahiri, Thomas

AU - Lubsch, Lisa

AU - Matsui, Jane

AU - Oermann, Christopher M.

AU - Ratjen, Felix

AU - Rosenfeld, Margaret

AU - Simon, Richard H.

AU - Hazle, Leslie

AU - Sabadosa, Kathy

AU - Marshall, Bruce C.

AU - Mueller, Gary

AU - Hadjiliadis, Denis

AU - Hoag, Jeffrey B.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Description: The Cystic Fibrosis (CF) Foundation developed clinical care guidelines for the prevention of Pseudomonas aeruginosa infection, the treatment of initial P. aeruginosa infection, and the use of bronchoscopy to obtain routine airway cultures in individuals with CF.Methods: A multidisciplinary committee developed questions about the prevention and treatment of initial P. aeruginosa infection and the use of bronchoscopy to obtain routine airway cultures. The outcome measure of interest was cultures without P. aeruginosa growth. Systematic reviews of PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials were conducted in May 2012 and August 2013. Searches combined controlled vocabulary terms and text words for CF and terms relevant to each question. The entire committee reviewed the evidence, and final recommendation statements were graded using the U.S. Preventive Services Task Force system.Recommendation 2: The CF Foundation recommends against the use of prophylactic antipseudomonal antibiotics to prevent the acquisition P. aeruginosa (certainty of net benefit, moderate; estimate of net benefit, zero; grade of recommendation, D).Recommendation 3: The CF Foundation recommends routine oropharyngeal cultures rather than bronchoalveolar lavage cultures obtained by bronchoscopy in individuals with CF who cannot expectorate sputum to determine if they are infected with P. aeruginosa (certainty of net benefit, moderate; estimate of net benefit, moderate; grade of recommendation, B).Recommendation 1: The CF Foundation strongly recommends inhaled antibiotic therapy for the treatment of initial or new growth of P. aeruginosa from an airway culture (certainty of net benefit, high; estimate of net benefit, substantial; grade of recommendation, A). The favored antibiotic regimen is inhaled tobramycin (300 mg twice daily) for 28 days.

AB - Description: The Cystic Fibrosis (CF) Foundation developed clinical care guidelines for the prevention of Pseudomonas aeruginosa infection, the treatment of initial P. aeruginosa infection, and the use of bronchoscopy to obtain routine airway cultures in individuals with CF.Methods: A multidisciplinary committee developed questions about the prevention and treatment of initial P. aeruginosa infection and the use of bronchoscopy to obtain routine airway cultures. The outcome measure of interest was cultures without P. aeruginosa growth. Systematic reviews of PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials were conducted in May 2012 and August 2013. Searches combined controlled vocabulary terms and text words for CF and terms relevant to each question. The entire committee reviewed the evidence, and final recommendation statements were graded using the U.S. Preventive Services Task Force system.Recommendation 2: The CF Foundation recommends against the use of prophylactic antipseudomonal antibiotics to prevent the acquisition P. aeruginosa (certainty of net benefit, moderate; estimate of net benefit, zero; grade of recommendation, D).Recommendation 3: The CF Foundation recommends routine oropharyngeal cultures rather than bronchoalveolar lavage cultures obtained by bronchoscopy in individuals with CF who cannot expectorate sputum to determine if they are infected with P. aeruginosa (certainty of net benefit, moderate; estimate of net benefit, moderate; grade of recommendation, B).Recommendation 1: The CF Foundation strongly recommends inhaled antibiotic therapy for the treatment of initial or new growth of P. aeruginosa from an airway culture (certainty of net benefit, high; estimate of net benefit, substantial; grade of recommendation, A). The favored antibiotic regimen is inhaled tobramycin (300 mg twice daily) for 28 days.

KW - Airway infection

KW - Antipseudomonal vaccine

KW - Bronchoscopy

KW - Inhaled antibiotics

KW - Oropharyngeal culture

UR - http://www.scopus.com/inward/record.url?scp=84920412587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920412587&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201404-166OC

DO - 10.1513/AnnalsATS.201404-166OC

M3 - Review article

VL - 11

SP - 1640

EP - 1650

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - 10

ER -